Publications by authors named "Leslie W Jacobson"
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis.
Neurol Neuroimmunol Neuroinflamm
November 2024
Background And Objectives: In this retrospective longitudinal study, we aimed at exploring the role of (a) MuSK-immunoglobulin G (IgG) levels, (b) predominant MuSK-IgG subclasses, and (c) antibody affinity as candidate biomarkers of severity and outcomes in MuSK-MG, using and comparing different antibody testing techniques.
Methods: Total MuSK-IgGs were quantified with radioimmunoassay (RIA), ELISA, flow cytometry, and cell-based assay (CBA) serial dilutions using HEK293 cells transfected with MuSK-eGFP. MuSK-IgG subclasses were measured by flow cytometry.
Article Synopsis
- In utero exposure to maternal antibodies against fetal acetylcholine receptors can cause severe conditions like arthrogryposis multiplex congenita (AMC) and the milder fetal acetylcholine receptor inactivation syndrome (FARIS), but the full impact remains unclear.
- A study of 46 cases reveals that many affected mothers did not have prior diagnoses of myasthenia gravis, suggesting underreporting and missed preventative measures.
- Among the findings, significant long-term effects in surviving infants included various physical weaknesses, respiratory issues, and unexpected conditions like hearing loss; treatment with oral salbutamol showed promising improvement in symptoms for many children.
Fetal acetylcholine receptor inactivation syndrome: A myopathy due to maternal antibodies.
Neurol Neuroimmunol Neuroinflamm
February 2015
Background: Transient neonatal myasthenia gravis (TNMG) affects a proportion of infants born to mothers with myasthenia gravis (MG). Symptoms usually resolve completely within the first few months of life, but persistent myopathic features have been reported in a few isolated cases.
Methods: Here we report 8 patients from 4 families born to mothers with clinically manifest MG or mothers who were asymptomatic but had elevated acetylcholine receptor (AChR) antibody levels.
Background: Identification of autoantibodies has defined distinct clinico-immuno-pathological subtypes of myasthenia gravis (MG) such as AChR-antibody-positive-MG and MuSK-antibody-positive-MG. The use of more sensitive assays such as the cell-based assay (CBA) is expected to reduce the proportion of seronegative-MG. We studied the seroprevalence of AChR and MuSK antibodies using both radioimmunoprecipitation (RIA) and CBA amongst MG patients in Sri Lanka and related their antibody status to their clinical subtypes and severity.
View Article and Find Full Text PDF